Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

The development of non-infectious subunit vaccines greatly increases the safety of prophylactic immunization, but also reinforces the need for a new generation of immunostimulatory adjuvants. Because adverse effects are a paramount concern in prophylactic immunization, few new adjuvants have received approval for use anywhere in the developed world. The vaccine adjuvant monophosphoryl lipid A is a detoxified form of the endotoxin lipopolysaccharide, and is among the first of a new generation of Toll-like receptor agonists likely to be used as vaccine adjuvants on a mass scale in human populations. Much remains to be learned about this compound's mechanism of action, but recent developments have made clear that it is unlikely to be simply a weak version of lipopolysaccharide. Instead, monophosphoryl lipid A's structure seems to have fortuitously retained several functions needed for stimulation of adaptive immune responses, while shedding those associated with pro-inflammatory side effects.

The matrix region is responsible for the differential ability of two retroviruses to function as helpers for vector propagation.

We have investigated the ability of two related reticuloendotheliosis viruses to propagate a spleen necrosis virus (SNV) based retroviral vector in canine osticosarcoma (D17) cells. Reticuloendotheliosis virus strain A (REV-A) consistently propagated the vector more efficiently than SNV in cell culture. To identify the area of the viral genome responsible for the superior helper function of REV-A, we constructed chimeric viruses between SNV and REV-A. Analysis of helper function indicated that a virus comprised of the SNV genome, but containing the matrix region of REV-A, could propagate the vector as well as REV-A. Although REV-A is also a superior virus for vector propagation in chicken embryo fibroblast cells, the region of the viral genome that confers superior helper function does not map to the gag region of REV-A in this cell type.

Mechanisms of lymphocyte killing by HIV.

One of the remaining mysteries of HIV infection is what causes the destruction of the CD4+ T cells. Several reports in the past year have linked viral load to disease progression, strengthening the conclusion that the virus is responsible for CD4+ T-cell depletion. We discuss several possible mechanisms of T-cell death, including the killing of uninfected CD4+ T cells. We also discuss the possibility that the virus protects the cell it infects at least until viral replication can be completed.

Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication.

The matrix domain of the Gag precursor protein, and the mature matrix protein, which is derived from processing of the Gag precursor, functions in several steps of the human immunodeficiency virus type-1 (HIV-1) life cycle. We made numerous mutations throughout the matrix protein and identified three mutants in the N-terminal portion of the matrix that drastically diminish the ability of the virus to replicate. Each of these replication-defective mutants was unable to acquire efficiently the envelope glycoprotein of HIV-1. To determine whether these same mutations affect other steps in viral replication we pseudotyped mutant particles with the envelope glycoprotein from an amphotropic murine leukemia virus. Each of these mutants was also hampered in other steps in virus replication. Two mutants were defective in entry or uncoating, and the third was hampered in a step following reverse transcription. Since viral replication was analyzed under conditions in which the nuclear localization function of the matrix protein is not required, the matrix protein may be required for an additional replication step following reverse transcription.

Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing.

The importance of the Fas death pathway in human immunodeficiency virus (HIV) infection has been the subject of many studies. Missing from these studies is direct measurement of infected cell susceptibility to Fas-induced death. To address this question, we investigated whether T cells infected with HIV are more susceptible to Fas-induced death. We found that Fas cross-linking caused a decrease in the number of HIV-infected Jurkat T cells and CD4(+) peripheral blood leukocytes (PBLs). We confirmed this finding by demonstrating that there were more apoptotic infected than uninfected cells after Fas ligation. The increase in sensitivity of HIV-infected cells to Fas killing mapped to vpu, while nef, vif, vpr, and second exon of tat did not appear to contribute. Furthermore, expression of Vpu in Jurkat T cells rendered them more susceptible to Fas-induced death. These results show that HIV-infected cells are more sensitive to Fas-induced death and that the Vpu protein of HIV contributes to this sensitivity. The increased sensitivity of HIV-infected cells to Fas-induced death might help explain why these cells have such a short in vivo half-life.

Mapping of HIV-1 determinants of apoptosis in infected T cells.

HIV-1 infection leads to death of CD4(+) T cells in vivo and in vitro, although the mechanisms of this cell death are not well defined. We used flow cytometry to concurrently analyze infection and apoptosis of the CD4(+) CEM T cell line and human peripheral blood mononuclear cells (PBMC). Surprisingly, T cells productively infected with HIV-1 IIIB showed less apoptosis than control, uninfected T cells. This relative paucity of apoptosis was a characteristic of IIIB, since a large number of cells infected with the viral clone, HIV-1 NL4-3, were apoptotic. The nef, vpr, and vpu gene products were not responsible for apoptosis of NL4-3-infected cells, since NL4-3DeltaVprDeltaVpuDeltaNef and HXB-2 (a nef, vpr, and vpu triple mutant derived from IIIB) also killed infected cells. Moreover, only IIIB-infected cells showed a resistance to background levels of apoptosis. Thus, the apoptotic (and antiapoptotic) properties of HIV-1 do not map solely to mutations in nef, vpr, or vpu. We postulate that, in vivo, HIV variants that do not induce rapid apoptosis in the cells they infect may have a selective advantage.